Nuvo Pharmaceuticals Ireland

Miravo Healthcare, formerly Nuvo Pharmaceuticals, is a commercial-stage specialty pharmaceutical company focused on pain management, allergy, and dermatology. The company operates through its subsidiary, Nuvo Pharmaceuticals Ireland, which serves as a strategic hub for managing international intellectual property and licensing agreements. Its diversified portfolio includes flagship products such as Pennsaid for osteoarthritis, Vimovo for inflammatory conditions, and Blexten for allergic rhinitis. Following its acquisition by Searchlight Pharma in 2023, and the subsequent acquisition of Searchlight by Apotex in 2024, the company continues to leverage its manufacturing and commercialization expertise. Miravo's business strategy emphasizes the acquisition of legacy brands and the development of proprietary drug delivery technologies.